期刊文献+

中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及平均血小板体积联合肿瘤标志物检测对小细胞肺癌的诊疗价值 被引量:1

The diagnostic value of neutrophil-to-lymphocyte ratio,platelet-to-lymphocyte ratio and mean platelet volume combined with tumor marker detection in small cell lung cancer
原文传递
导出
摘要 目的旨在探讨中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)及平均血小板体积(MPV)联合肿瘤标志物检测对小细胞肺癌的诊疗价值。方法回顾性分析207例小细胞肺癌患者及207例体检者肿瘤标志物神经元特异性烯醇化酶(NSE)、胃泌素释放肽前体(pro GRP)和炎性指标NLR、PLR、MPV的检测数据,比较不同分期、治疗前后检测结果的差异,采用ROC曲线评估单项和联合指标对小细胞肺癌的诊断价值。结果小细胞肺癌患者广泛期和局限期5项指标均存在统计学差异(P<0.05)。首次治疗后proGRP、NSE、NLR、PLR和MPV分别下降了73.17%、59.53%、31.52%、11.89%和3.00%,均存在统计学差异(P<0.05)。NSE和pro GRP联合检测敏感度为89.40%,特异度为93.20%,约登指数为0.826,高于单独检测。NSE+proGRP联合NLR、PLR、MPV和NSE+proGRP相比,诊断价值不存在统计学差异(P>0.05)。结论肿瘤标志物NSE和pro GRP联合检测对小细胞肺癌的诊断价值高于单独检测,联合炎性指标NLR、PLR、MPV诊断价值未有明显提升,但NLR、PLR、MPV均可用于小细胞肺癌治疗效果评估。 Objective The purpose of this study was to investigate the diagnostic value of neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR)and mean platelet volume(MPV)combined with tumor marker detection for small cell lung cancer.Methods The detection data of tumor markers neuron-specific enolase(NSE),pro-gastrin-releasing peptide(pro GRP)and inflammatory indicators NLR,PLR and MPV in 207 patients with small cell lung cancer and normal control were retrospectively analyzed;the differences in detection results between different stages and treatment process were compared,and ROC curves were used to evaluate the diagnostic value of single and combined indicators for small cell lung cancer.Results There were significant differences in the five indicators between the extensive stage and the limited stage of patients with small cell lung cancer(P<0.05).After the first treatment,pro GRP,NSE,NLR,PLR and MPV decreased by 73.17%,59.53%,31.52%,11.89%and 3.00%,respectively(P<0.05).The combined detection sensitivity of NSE and proGRP was 89.40%,the specificity was 93.20%,and the Youden index was 0.826,which was higher than the single detection.There was no statistical difference in the diagnostic value of NSE+proGRP combined with NLR,PLR,MPV and NSE+proGRP(P>0.05).Conclusion The diagnostic value of NSE combined with proGRP was higher than single detection in small cell lung cancer.The diagnostic value of NLR,PLR and MPV combined with NSE+proGRP did not improve significantly.However,NLR,PLR and MPV could all be used to evaluate the therapeutic effect of small cell lung cancer.
作者 姚晓宾 许青霞 盛家和 YAO Xiaobin;XU Qingxia;SHENG Jiahe(Department of Clinical Laboratory,Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450008,China)
出处 《河南预防医学杂志》 2022年第9期713-717,共5页 Henan Journal of Preventive Medicine
关键词 小细胞肺癌 中性粒细胞与淋巴细胞比值 血小板与淋巴细胞比值 神经元特异性烯醇化酶 胃泌素释放肽前体 评估 Small cell lung cancer Neutrophil-to-lymphocyte ratio(NLR) Platelet-to-lymphocyte ratio(PLR) Neuron specific enolase(NSE) Pro-gastrin releasing peptide(proGRP) Evaluation
  • 相关文献

参考文献2

二级参考文献63

  • 1Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.J Clin Oncol, 2002, 20(24): 4665-4672.
  • 2Siu LL, Shepherd FA, Murray N, et al. Influence of age on the treatment of limited-stage small-cell lung cancer.J Clin Oncol, 1996, 14(3): 821-828.
  • 3Jara c, Gomez-Aldaravi JL, Tirado R, et al. Small-cell lung cancer in the elderly-is age of patient a relevant factor? Acta Oncol, 1999, 38(6): 781-786.
  • 4Noguchi T, Mochizuki H, Yamazaki M, et al. A retrospective analysis of clinical outcomes of patients older than or equal to 80 years with small cell lung cancer.J Thora Oncol, 2010, 5(7): 1081-1087.
  • 5Caprario LC, Kent DM, Trikalinos TA, et al. Determinants of chemotherapy administration and effects of chemotherapy on survival in elderly patients with small cell lung cancer (SCLC): A SEER-medicare analysis. J Clin Oncol, 2011, 29(15 S): 7083 [abstract].
  • 6Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev, 2011, 37(2): 143-150.
  • 7Von Pawel J, Gatzemeier U, PujolJL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.J Clin Oncol, 2001, 19(6): 1743-1749.
  • 8Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol, 2007, 25 (15 ) : 2086-2092.
  • 9O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.J Clin Oncol, 2006, 24(34): 5441-5447.
  • 10von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 1999, 17(2): 658-667.

共引文献17

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部